Indian Pharmas Look To Own Brand Extensions In Combo Market
This article was originally published in PharmAsia News
Executive Summary
Indian pharmas are increasingly drawn to applying for brand extensions as they adopt a strategy usually confined to foreign drug makers. The change is due to the popularity of combination drugs in the Indian market, according to a study by ORG IMS. The research firm's report said a third of every new drug launched in India qualify for the term brand extension, accounting for about 18 percent of sales in the country. Analysts see a large increase in brand extensions yet to come as physicians overwhelmed with new products settle for brands they recognize. (Click here for more
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.